Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 180 for “"Endocrine Therapy"”.
-
Etiological Factors and Endocrine Therapy in Involutional Melancholia
Abstract Not Provided.
-
Identification of Endocrine Therapy Induced Targetable Vulnerabilities in Cancer
… receptor (ESR1), respectively, and as such, endocrine therapies targeting the actions of these receptors has been a cornerstone of treatment for these patients. While these endocrine therapies are generally initially efficacious, resistance inevitably emerges. Resistance can emerge through …
-
Understanding adherence to adjuvant endocrine therapy in breast cancer survivors
Background: Adjuvant endocrine therapy (AET) is highly efficacious, significantly reducing breast cancer recurrence and mortality for women with hormone receptor-positive breast cancer. Yet, many women do not adhere to prescribed AET. The purpose of this study was to explore breast cancer …
-
Targeting mdr1 and endocrine therapy-resistant cancers through estrogen receptor
… BHPI blocked growth and often killed diverse therapy-resistant and ER-positive breast, ovarian, and endometrial cancer cells. Moreover, in a mouse xenograft, BHPI treatment resulted in rapid and substantial regression of pre-existing tumors. Extending the novel action of BHPI by …
-
Epigenetic Targeting to Deplete Cytostatic Breast cancer cells under Endocrine Therapy
… cytostatic cancer cells under hormonal therapy. In this thesis, I worked with other members in the laboratory to determine the efficacy and selectivity of clinical-grade HDAC inhibitors in depleting persistent cytostatic breast cancer cells under tamoxifen treatments and explore the …
-
Endocrine therapy mediated hot flushes in breast cancer: can exercise help?
… sweating. Hot flushes are a side effect of endocrine therapy for breast cancer treatment; and are possibly more frequent and severe than post-menopausal hot flushes. Many breast cancer patients do not adhere to the endocrine therapy guidelines due to the frequency and severity of hot …
-
Elucidating the Endocrine Therapy Experiences of South Carolina Breast Cancer Survivors
The aims of this study were to 1) describe endocrine therapy (ET) non-initiation, non-adherence, and duration by age, race, and temporal trend; 2) identify demographic, clinical, and pharmaceutical factors that are associated with an individual’s ET usage; and 3) understand from the survivor …
-
Adherence to Adjuvant Endocrine Therapy among Women Diagnosed with Early Breast Cancer
… cancer cases in the US. Treatment with adjuvant endocrine therapy (AET) is recommended for five years for women with ER+ breast cancer. Despite the effectiveness of AET to improve survival and decrease cancer recurrence, adherence to recommended treatment is suboptimal. Understanding the factors …
-
The impact of nonsteroidal anti-inflammatory drugs on endocrine therapy outcomes in breast cancer patients
… using NSAID use, BMI categories and hormonal therapy drug as independent variables to predict recurrence, use of NSAID was only statistically significant in the univariate model. Overweight women were more likely to develop recurrence than normal weight when holding NSAID use and endocrine …
-
Meta-analysis of randomized clinical evidence of chemotherapy, radiotherapy and endocrine therapy in breast cancer
… the use of various treatment strategies (chemotherapy, endocrine therapy, radiotherapy) in breast cancer, the efficacy of some strategies remains unclear and questionable. A meta-analysis, by combining the results of all available trials that studied the same question, could help to reduce the …
-
Adjuvant endocrine therapy use in female breast cancer survivors and the risk of cardiovascular disease
… receptor positive breast cancer are prescribed endocrine therapies, tamoxifen or aromatase inhibitors (AI), to block the effects of oestrogen on the growth of tumour cells. Tamoxifen is known to be associated with an increased risk of venous thromboembolic events, but the long-term effect of …
-
The Role of Estrogen Receptor Mutations and Receptor Tyrosine Kinase Alterations in Driving Endocrine Therapy Resistance
… common clinical subtype, is treated with anti-ER endocrine therapies as a first-line treatment. However, resistance to endocrine therapy develops in almost all patients with metastatic ER-positive breast cancer and remains an unmet medical need. In paired pre- and post-treatment patient biopsies, …
-
Elucidating the mechanisms of resistance to CDK4/6 inhibitors and endocrine therapy in ER+ breast cancer
CDK4/6 inhibitors in combination with endocrine therapy have recently become standard-of-care for treatment of advanced/metastatic ER+ breast cancer. Despite initial improvements in patient responses, resistance to combination endocrine–CDK4/6 inhibitor therapy is rapidly emerging. While there have …
-
Treatment Side Effects & Nonadherence among Women Taking Adjuvant Endocrine Therapy for Breast Cancer: The Role of Psychological Factors
Nonadherence to adjuvant endocrine therapy with either tamoxifen or aromatase inhibitors significantly increases the risk of breast cancer recurrence. Side effects are a key driver of nonadherence to these treatments. As part of this doctoral research, two studies were conducted to explore the …
-
A Time to Question: A Study of the Information Needs of Postmenopausal Breast Cancer Patients Regarding Endocrine Therapy
… cancer making treatment decisions regarding endocrine therapy. An integrative review of research was conducted to collate and describe the information needs assessment methodologies used to identify information needs for women with breast cancer. Based on this review and our long-term goal of …
-
Aspects of Endocrine Therapy in Primary Breast Cancer. Risk Profiling and Adherence Perspectives for Improving Tailored Adjuvant Treatment.
… tumours are generally recommended adjuvant chemotherapy in addition to endocrine therapy. The agreement between the subtyping by gene expression and surrogate classification, is not perfect. Prosigna® test provides the tumour subtype and assigns the patient a relapse risk score (Risk of …
-
Clinical biomarkers of response to neoadjuvant endocrine therapy in breast cancer: exploring the potential of gene expression data integration
… approach a classifier of clinical response to endocrine therapy in the neoadjuvant setting based on the expression of 4 genes was developed which predicted response with 96% and 91% accuracy in training (n=73) and independent validation (n=44) datasets respectively. An early on-treatment biopsy …
Page 1 of 9